Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Basch

Interventional Pain Medicine Wyoming, MI Medical Doctor

NPI 1619930575 CMS profile 27614

2147 Health Dr Sw Ste 100, Ste 100, Wyoming, MI 49519

Open in the dashboard

General payments

$2,739

54 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Basch of Wyoming, MI is reported in the CMS Open Payments database as having received $2,739 across 54 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 41st percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $997 9
2024 General $1,178 12
2023 General $35 1
2022 General $175 9
2021 General $125 7
2020 General $61 4
2019 General $169 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Basch
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Thomas Basch were reported at $997. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Thomas Basch Interventional Pain Medicine median Middle half National median
2019 $169 $684 $216–$2,079 $163
2020 $61 $382 $122–$1,109 $114
2021 $125 $552 $167–$1,554 $132
2022 $175 $605 $187–$1,924 $149
2023 $35 $671 $195–$1,915 $160
2024 $1,178 $684 $206–$1,837 $164
2025 $997 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,182 22 payments
  2. AbbVie, Inc. $89 4 payments
  3. Allergan Inc. $53 4 payments
  4. Supernus Pharmaceuticals, Inc. $47 3 payments
  5. Biogen, Inc. $41 2 payments
  6. Boston Scientific Corporation $35 2 payments
  7. Piramal Critical Care $32 2 payments
  8. Vertical Pharmaceuticals, LLC $30 2 payments
  9. Teva Pharmaceuticals USA, Inc. $29 2 payments
  10. Amgen Inc. $28 1 payment
  11. Other $175 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $1,667 9 payments
  2. Food and Beverage $1,073 45 payments
Products named General payments · program years 2019–2025
  1. PROCLAIM Neuromodulation $1,096 8 payments
  2. PROCLAIM Structural Heart $997 9 payments
  3. UBRELVY $72 3 payments
  4. Proclaim IPG $54 3 payments
  5. BOTOX $53 4 payments
  6. TROKENDI XR $47 3 payments
  7. ADUHELM $41 2 payments
  8. GABLOFEN $32 2 payments
  9. GABLOFEN 1 mL in 1 SYRINGE, GLASS $32 2 payments
  10. LORZONE $30 2 payments
  11. Other $319 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

38

Median for Interventional Pain Management: 1,220

Drug cost

$2,039

Median for Interventional Pain Management: $39,344

Branded share of claims

100%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Progesterone Progesterone, Micronized Brand 15 $1,547
Armour Thyroid Thyroid,pork Brand 11 $372
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 12 $120

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Records

54 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record